Exercise Study in Patient With Chronic Obstructive Pulmonary Disease (0000-036)
NCT ID: NCT00387036
Last Updated: 2016-01-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
12 participants
INTERVENTIONAL
2006-12-31
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01168310
A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease
NCT01033487
A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations
NCT00116402
A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)
NCT00482235
Effects of Inhaled Corticosteroids in the Systemic Inflammation Induced by Exercise in Patients With COPD
NCT02209974
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Arm 1: drug, crossing over to Pbo comparator
Fluticasone
fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.
2
Arm 2: Pbo comparator, crossing over to drug
Fluticasone
fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.
Comparator: Placebo
Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fluticasone
fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.
Comparator: Placebo
Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical diagnosis of COPD for greater than one year
* History of cigarette smoking
Exclusion Criteria
* A condition that could interfere with your ability to perform exercise tests
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
References
Explore related publications, articles, or registry entries linked to this study.
Guenette JA, Raghavan N, Harris-McAllister V, Preston ME, Webb KA, O'Donnell DE. Effect of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD. Respir Med. 2011 Dec;105(12):1836-45. doi: 10.1016/j.rmed.2011.08.021. Epub 2011 Sep 13.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
036
Identifier Type: -
Identifier Source: secondary_id
2006_039
Identifier Type: -
Identifier Source: secondary_id
0000-036
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.